title: Management of ductal carcinoma in situ.
abstract: The dramatic increase in the incidence of ductal carcinoma in situ (DCIS) of the breast has made it imperative for all clinicians to develop a better understanding of this disease. Although this preinvasive form of breast cancer is not life-threatening, treatment options may include mastectomy, breast-conserving surgery, radiotherapy, or tamoxifen. Current treatment modalities may be overly aggressive because many cases of DCIS may not recur or progress to invasive cancer. Until we are better able to identify those patients at low risk for progression, it is unlikely that current treatment will change. The adequate understanding of risk assessment is fundamental to the treatment planning for DCIS, and physicians are encouraged to include patients in the decision-making process.
authors.affiliation: Department of Surgery, University of California, San Francisco, USA.
authors.forename: E S
authors.initials: ES
authors.lastname: Hwang
authors.forename: L J
authors.initials: LJ
authors.lastname: Esserman
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D002278:Carcinoma in Situ / Q000532:radiotherapy / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000532:radiotherapy / Q000628:therapy*; D018450:Disease Progression; D005260:Female; D006801:Humans; D015994:Incidence; D008408:Mastectomy; D015412:Mastectomy, Segmental; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010347:Patient Care Planning; D010358:Patient Participation; D018570:Risk Assessment; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen